首页 > 最新文献

Urologia Internationalis最新文献

英文 中文
Comparison of the Role of Anticholinergics and α-1 Adrenergic Blockers in Bladder Management in Posterior Urethral Valves: A Pilot Randomized Control Trial. 比较抗胆碱能药和α-1肾上腺素能阻滞剂在后尿道瓣膜膀胱管理中的作用:随机对照试验。
IF 1.5 4区 医学 Q3 UROLOGY & NEPHROLOGY Pub Date : 2024-10-03 DOI: 10.1159/000541245
Ramyasree Bade, Jai Kumar Mahajan, Akshay Kalavant, Saswati Behera, Palak Singhai, Akshay Saxena

Introduction: Posterior urethral valve (PUV) is a major cause of congenital bladder dysfunction, often persisting despite treatment. Emerging therapies, including anticholinergics and α-1 blockers, offer potential but lack clear guidelines. This study evaluates their effectiveness in improving bladder function after valve fulguration.

Methods: Twenty posterior urethral valve patients, aged ≥3 years, were randomized into Anticholinergic (group A, n=11) and α-1 adrenergic blocker (group B, n=9) groups post-fulguration. Follow-up included clinical, radiological, and urodynamic assessments six months post-treatment initiation.

Results: In group A, the mean maximum detrusor pressure (Pdet) decreased from 30.17 to 23.45 cm H2O (p= 0.033). Two patients normalized from high detrusor pressure (>40 cm H2O). In group B, one patient retained high detrusor pressure post-treatment. Group B improved in Q avg and Q max, with all patients having initially low Q avg (<10 ml/sec). Two group B patients showed improved average flow rates post-treatment (p=0.016); three in group A showed improvement, but were not statistically significant (p=0.197). Q max/flow time ratio was abnormal in all group B patients pre-treatment. Two of the nine improved post-treatment, while only one in group A did.

Conclusions: Anticholinergic medications positively impact cystometric parameters and are effective for detrusor instability and low compliance bladder. α-adrenergic blockers influence uroflow parameters and can help treat bladder outflow obstruction. Consideration for a larger study with extended follow-up is warranted.

简介:后尿道瓣膜(PUV)是导致先天性膀胱功能障碍的主要原因之一,尽管经过治疗,但往往仍会持续存在。包括抗胆碱能药和α-1受体阻滞剂在内的新兴疗法具有潜力,但缺乏明确的指导方针。本研究评估了它们在瓣膜成形术后改善膀胱功能的有效性:20名年龄≥3岁的后尿道瓣膜患者在瓣膜成形术后随机分为抗胆碱能药物组(A组,n=11)和α-1肾上腺素能阻滞剂组(B组,n=9)。随访包括治疗开始后六个月的临床、放射学和尿动力学评估:结果:在 A 组中,平均最大逼尿肌压力(Pdet)从 30.17 厘米 H2O 降至 23.45 厘米 H2O(p= 0.033)。两名患者从高逼尿压力(40 cm H2O)恢复正常。在 B 组中,有一名患者在治疗后仍保持较高的排尿压。B 组患者的平均 Q 值和最大 Q 值均有所改善,但所有患者最初的平均 Q 值都较低(10 毫升/秒)。治疗后,B 组有两名患者的平均流速有所改善(P=0.016);A 组有三名患者的平均流速有所改善,但无统计学意义(P=0.197)。治疗前,所有 B 组患者的 Q 最大值/流速时间比均不正常。九名患者中有两名在治疗后有所改善,而 A 组中只有一名患者有所改善:结论:抗胆碱能药物对膀胱测量参数有积极影响,对逼尿肌不稳定和低顺应性膀胱有效。有必要考虑进行更大规模的研究,并延长随访时间。
{"title":"Comparison of the Role of Anticholinergics and α-1 Adrenergic Blockers in Bladder Management in Posterior Urethral Valves: A Pilot Randomized Control Trial.","authors":"Ramyasree Bade, Jai Kumar Mahajan, Akshay Kalavant, Saswati Behera, Palak Singhai, Akshay Saxena","doi":"10.1159/000541245","DOIUrl":"https://doi.org/10.1159/000541245","url":null,"abstract":"<p><strong>Introduction: </strong>Posterior urethral valve (PUV) is a major cause of congenital bladder dysfunction, often persisting despite treatment. Emerging therapies, including anticholinergics and α-1 blockers, offer potential but lack clear guidelines. This study evaluates their effectiveness in improving bladder function after valve fulguration.</p><p><strong>Methods: </strong>Twenty posterior urethral valve patients, aged ≥3 years, were randomized into Anticholinergic (group A, n=11) and α-1 adrenergic blocker (group B, n=9) groups post-fulguration. Follow-up included clinical, radiological, and urodynamic assessments six months post-treatment initiation.</p><p><strong>Results: </strong>In group A, the mean maximum detrusor pressure (Pdet) decreased from 30.17 to 23.45 cm H2O (p= 0.033). Two patients normalized from high detrusor pressure (&gt;40 cm H2O). In group B, one patient retained high detrusor pressure post-treatment. Group B improved in Q avg and Q max, with all patients having initially low Q avg (&lt;10 ml/sec). Two group B patients showed improved average flow rates post-treatment (p=0.016); three in group A showed improvement, but were not statistically significant (p=0.197). Q max/flow time ratio was abnormal in all group B patients pre-treatment. Two of the nine improved post-treatment, while only one in group A did.</p><p><strong>Conclusions: </strong>Anticholinergic medications positively impact cystometric parameters and are effective for detrusor instability and low compliance bladder. α-adrenergic blockers influence uroflow parameters and can help treat bladder outflow obstruction. Consideration for a larger study with extended follow-up is warranted.</p>","PeriodicalId":23414,"journal":{"name":"Urologia Internationalis","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142372983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transformations in BPH Surgical Practices: A Longitudinal Study of Trends and Predictions. 良性前列腺增生手术实践的转变:趋势与预测的纵向研究。
IF 1.5 4区 医学 Q3 UROLOGY & NEPHROLOGY Pub Date : 2024-10-03 DOI: 10.1159/000541752
Karin Lifshitz, Ziv Savin, Tomer Bashi, Snir Dekalo, Hen Hendel, Yaron Ehrlich, Omer Anis, Zohar Dotan, Guy Verhovsky, Ehud Genessin, Rabeea Moed, Nicola Mabjeesh, Mahmoud Abbas, Ilan Kafka, Ali Safadi, Ran Katz, Ofer Yossepowitch, Mario Sofer

Introduction: The workload for BPH surgery is expected to rise with an increase in life expectancy and a growing population. Surgical modalities for BPH have evolved, shifting towards minimally invasive transurethral procedures. This study aims to investigate the trends in BPH surgical procedures across medical centers in Israel.

Methods: Data from seven academic medical centers in Israel from 2010 to 2022 were analyzed. Procedures included open prostatectomy, transurethral prostatectomy (TURP), laser enucleation of the prostate (HoLEP), and photovaporization of the prostate (PVP). Statistical analyses were employed, including t-tests, ANOVA, and ARIMA models.

Results: Over 12 years, 13,478 BPH procedures were performed. TURP was the most common (72%), followed by open surgery (12%), HoLEP (12%), and PVP (3%). Annual procedures increased by approximately 5% each year, with a cumulative surge of 63% cases by 2022. The average patient's age remained stable. TURP and HoLEP showed continual growth, while open surgery declined. HoLEP exhibited a shorter length of hospital stay compared to other modalities. Predictive models suggest open prostatectomy will cease within two years, while TURP and HoLEP will continue to rise.

Conclusion: This study highlights a significant increase in BPH surgical procedures over time, with a notable preference for TURP and HoLEP. The findings emphasize the importance of size-independent techniques like HoLEP for optimal healthcare management in the future.

导言:随着预期寿命的延长和人口的增长,良性前列腺增生手术的工作量预计会增加。良性前列腺增生症的手术方式也在不断发展,逐渐转向经尿道微创手术。本研究旨在调查以色列各医疗中心良性前列腺增生手术的发展趋势:分析了以色列七家学术医疗中心 2010 年至 2022 年的数据。手术包括开放性前列腺切除术、经尿道前列腺切除术(TURP)、前列腺激光去核术(HoLEP)和前列腺光汽化术(PVP)。统计分析包括t检验、方差分析和ARIMA模型:结果:12年间,共进行了13,478例良性前列腺增生手术。TURP最常见(72%),其次是开放手术(12%)、HoLEP(12%)和PVP(3%)。年手术量每年增加约 5%,到 2022 年,手术量将累计激增 63%。患者的平均年龄保持稳定。TURP和HoLEP持续增长,而开放手术有所下降。与其他方式相比,HoLEP的住院时间更短。预测模型显示,开放式前列腺切除术将在两年内停止,而TURP和HoLEP将继续上升:这项研究表明,随着时间的推移,良性前列腺增生症手术的数量将大幅增加,而前列腺电切术(TURP)和前列腺电切术(HoLEP)将成为首选。研究结果强调了HoLEP等与体型无关的技术对未来优化医疗管理的重要性。
{"title":"Transformations in BPH Surgical Practices: A Longitudinal Study of Trends and Predictions.","authors":"Karin Lifshitz, Ziv Savin, Tomer Bashi, Snir Dekalo, Hen Hendel, Yaron Ehrlich, Omer Anis, Zohar Dotan, Guy Verhovsky, Ehud Genessin, Rabeea Moed, Nicola Mabjeesh, Mahmoud Abbas, Ilan Kafka, Ali Safadi, Ran Katz, Ofer Yossepowitch, Mario Sofer","doi":"10.1159/000541752","DOIUrl":"https://doi.org/10.1159/000541752","url":null,"abstract":"<p><strong>Introduction: </strong>The workload for BPH surgery is expected to rise with an increase in life expectancy and a growing population. Surgical modalities for BPH have evolved, shifting towards minimally invasive transurethral procedures. This study aims to investigate the trends in BPH surgical procedures across medical centers in Israel.</p><p><strong>Methods: </strong>Data from seven academic medical centers in Israel from 2010 to 2022 were analyzed. Procedures included open prostatectomy, transurethral prostatectomy (TURP), laser enucleation of the prostate (HoLEP), and photovaporization of the prostate (PVP). Statistical analyses were employed, including t-tests, ANOVA, and ARIMA models.</p><p><strong>Results: </strong>Over 12 years, 13,478 BPH procedures were performed. TURP was the most common (72%), followed by open surgery (12%), HoLEP (12%), and PVP (3%). Annual procedures increased by approximately 5% each year, with a cumulative surge of 63% cases by 2022. The average patient's age remained stable. TURP and HoLEP showed continual growth, while open surgery declined. HoLEP exhibited a shorter length of hospital stay compared to other modalities. Predictive models suggest open prostatectomy will cease within two years, while TURP and HoLEP will continue to rise.</p><p><strong>Conclusion: </strong>This study highlights a significant increase in BPH surgical procedures over time, with a notable preference for TURP and HoLEP. The findings emphasize the importance of size-independent techniques like HoLEP for optimal healthcare management in the future.</p>","PeriodicalId":23414,"journal":{"name":"Urologia Internationalis","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142372986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sustained response to anti-PD-1 therapy in combination with nab-paclitaxel in metastatic testicular germ cell tumor harboring the KRAS-G12V mutation: a case report. 携带KRAS-G12V突变的转移性睾丸生殖细胞瘤对KRAS-G12V突变的抗PD-1联合纳布紫杉醇疗法的持续反应:病例报告。
IF 1.5 4区 医学 Q3 UROLOGY & NEPHROLOGY Pub Date : 2024-10-03 DOI: 10.1159/000541588
Jinfeng Pan, Weiqi Yin, Yingzhi Chen, Hui Wang, Wei Wu, Suying Wang, Da Li, Qi Ma

Introduction: Cisplatin-based standardized therapy has been established for metastatic testicular germ cell tumors (TGCTs). However, the patient prognosis is considerably less favorable if the disease recurs following failure of first-line therapies. There is a need for novel treatment options for patients with recurrent or metastatic TGCTs, notably for those that are not sensitive to first-line chemotherapy. With the development of next-generation sequencing technologies, an increasing number of gene mutations has been identified in TGCTs. Previously published research studies have established a link between KRAS mutations and chemotherapy resistance, and have demonstrated that KRAS mutations are associated with inflammatory tumor microenvironment and tumor immunogenicity, leading to an improved response to inhibition of programmed death (PD-1) protein expression. Previous studies have reported that the tumor immune microenvironment of TGCT influences therapeutic efficacy.

Case presentation: A65-year-old metastatic patient with TGCT and a KRAS-12 valine-for glycine gene mutation was described. This patient initially underwent inguinal orchiectomy and received two prior chemotherapeutic regimens. Following the rapid progression of the disease, the patient was treated with anti-PD-1 therapy and nab paclitaxel chemotherapy, and his condition was successfully controlled by this combination treatment.

Conclusion: To the best of our knowledge, this is the first successful case of KRAS-mutation patient with TGCT who achieved partially and sustained disease remission by combining immune checkpoint inhibitors with chemotherapy. This case provides an excellent example for personalized treatment of metastatic TGCTs.

简介对于转移性睾丸生殖细胞肿瘤(TGCTs),以顺铂为基础的标准化疗法已经确立。然而,如果一线治疗失败后疾病复发,患者的预后就会大打折扣。复发或转移性 TGCT 患者需要新的治疗方案,尤其是对一线化疗不敏感的患者。随着新一代测序技术的发展,在 TGCTs 中发现的基因突变越来越多。此前发表的研究已确定了 KRAS 突变与化疗耐药性之间的联系,并证明 KRAS 突变与炎症性肿瘤微环境和肿瘤免疫原性有关,导致对抑制程序性死亡(PD-1)蛋白表达的反应改善。之前的研究报告称,TGCT 的肿瘤免疫微环境影响了疗效:本病例描述了一名 65 岁的 TGCT 转移性患者,其 KRAS-12 缬氨酸-甘氨酸基因突变。该患者最初接受了腹股沟睾丸切除术,并接受了两种化疗方案。随着病情的快速进展,患者接受了抗PD-1疗法和奈普紫杉醇化疗,并通过这种联合疗法成功控制了病情:据我们所知,这是首例KRAS突变的TGCT患者通过将免疫检查点抑制剂与化疗相结合而获得部分和持续疾病缓解的成功病例。该病例为转移性 TGCT 的个性化治疗提供了一个很好的范例。
{"title":"Sustained response to anti-PD-1 therapy in combination with nab-paclitaxel in metastatic testicular germ cell tumor harboring the KRAS-G12V mutation: a case report.","authors":"Jinfeng Pan, Weiqi Yin, Yingzhi Chen, Hui Wang, Wei Wu, Suying Wang, Da Li, Qi Ma","doi":"10.1159/000541588","DOIUrl":"https://doi.org/10.1159/000541588","url":null,"abstract":"<p><strong>Introduction: </strong>Cisplatin-based standardized therapy has been established for metastatic testicular germ cell tumors (TGCTs). However, the patient prognosis is considerably less favorable if the disease recurs following failure of first-line therapies. There is a need for novel treatment options for patients with recurrent or metastatic TGCTs, notably for those that are not sensitive to first-line chemotherapy. With the development of next-generation sequencing technologies, an increasing number of gene mutations has been identified in TGCTs. Previously published research studies have established a link between KRAS mutations and chemotherapy resistance, and have demonstrated that KRAS mutations are associated with inflammatory tumor microenvironment and tumor immunogenicity, leading to an improved response to inhibition of programmed death (PD-1) protein expression. Previous studies have reported that the tumor immune microenvironment of TGCT influences therapeutic efficacy.</p><p><strong>Case presentation: </strong>A65-year-old metastatic patient with TGCT and a KRAS-12 valine-for glycine gene mutation was described. This patient initially underwent inguinal orchiectomy and received two prior chemotherapeutic regimens. Following the rapid progression of the disease, the patient was treated with anti-PD-1 therapy and nab paclitaxel chemotherapy, and his condition was successfully controlled by this combination treatment.</p><p><strong>Conclusion: </strong>To the best of our knowledge, this is the first successful case of KRAS-mutation patient with TGCT who achieved partially and sustained disease remission by combining immune checkpoint inhibitors with chemotherapy. This case provides an excellent example for personalized treatment of metastatic TGCTs.</p>","PeriodicalId":23414,"journal":{"name":"Urologia Internationalis","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142372985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of SARS-CoV-2-Pandemic on diagnosis of prostate cancer. SARS-CoV-2大流行对前列腺癌诊断的影响。
IF 1.5 4区 医学 Q3 UROLOGY & NEPHROLOGY Pub Date : 2024-10-03 DOI: 10.1159/000541753
Immanuel A Oppolzer, Marco J Schnabel, Selma Hammer, Hannah Zilles, Maximilian Haas, Christopher Goßler, Maximilian R Müller, Maximilian Burger, Michael Gierth

Introduction The aim of this study was to prove if the SARS-CoV-2-pandemic resulted in a delay in diagnosis and treatment of prostate cancer (PC). Methods A monocentric, retrospective analysis was conducted at a university cancer center. Included were all patients with untreated PC diagnosed between January 2019 and December 2021. The observation covered 22 months of the SARS-CoV-2-pandemic and 14 months preceding it. Results 969 men prior (T0) and 1343 during pandemic (T1) where included. Mean age was 68.0 (SD 8.2). Median initial PSA was 8.1 ng/ml (T0) and 7.9 ng/ml (T1, p= 0.288). Time from biopsy to tumor board (T0: 1.3 months vs. T1: 0.9 months, p=0.001), to staging (T0: 1,1 months vs. T1: 0.75 months, p=0.707) and to therapy (T0: 3.0 months vs. T1: 2.0 months, p<0.001) were shortened during pandemic. Classified by d'Amico, a significant shift towards higher risk groups was seen (p=0.024). Local staging showed an insignificant increase in locally advanced PCs. Metastatic diseases decreased from 10.3 % to 8.9% (p=0.433). Pathological staging showed pT3+ in 44.4% vs. 44.7% (p=0.565) and pN+ in 9.9 % vs 9.6% (p=0.899). Conclusion Regarding the diagnosis and treatment of PC, we could not demonstrate any delays due to the SARS-CoV-2-pandemic.

引言 本研究旨在证明 SARS-CoV-2 大流行是否导致了前列腺癌(PC)诊断和治疗的延误。方法 在一所大学癌症中心进行了单中心回顾性分析。研究对象包括在 2019 年 1 月至 2021 年 12 月期间确诊的所有未经治疗的 PC 患者。观察时间涵盖 SARS-CoV-2 大流行期间的 22 个月和之前的 14 个月。结果 纳入了969名之前(T0)和1343名大流行期间(T1)的男性患者。平均年龄为 68.0 (SD 8.2)。初始 PSA 中位数为 8.1 纳克/毫升(T0)和 7.9 纳克/毫升(T1,P= 0.288)。大流行期间,从活检到肿瘤检查(T0:1.3 个月 vs. T1:0.9 个月,p=0.001)、分期(T0:1.1 个月 vs. T1:0.75 个月,p=0.707)和治疗(T0:3.0 个月 vs. T1:2.0 个月,p<0.001)的时间都缩短了。按 d'Amico 分类,高危人群明显增加(p=0.024)。局部分期显示,局部晚期 PCs 的增加并不明显。转移性疾病从 10.3% 降至 8.9%(P=0.433)。病理分期显示,44.4%的患者为pT3+,44.7%的患者为pN+(p=0.565),9.9%的患者为pN+,9.6%的患者为pN+(p=0.899)。结论 在 PC 的诊断和治疗方面,我们没有发现任何因 SARS-CoV-2 大流行而导致的延误。
{"title":"Impact of SARS-CoV-2-Pandemic on diagnosis of prostate cancer.","authors":"Immanuel A Oppolzer, Marco J Schnabel, Selma Hammer, Hannah Zilles, Maximilian Haas, Christopher Goßler, Maximilian R Müller, Maximilian Burger, Michael Gierth","doi":"10.1159/000541753","DOIUrl":"https://doi.org/10.1159/000541753","url":null,"abstract":"<p><p>Introduction The aim of this study was to prove if the SARS-CoV-2-pandemic resulted in a delay in diagnosis and treatment of prostate cancer (PC). Methods A monocentric, retrospective analysis was conducted at a university cancer center. Included were all patients with untreated PC diagnosed between January 2019 and December 2021. The observation covered 22 months of the SARS-CoV-2-pandemic and 14 months preceding it. Results 969 men prior (T0) and 1343 during pandemic (T1) where included. Mean age was 68.0 (SD 8.2). Median initial PSA was 8.1 ng/ml (T0) and 7.9 ng/ml (T1, p= 0.288). Time from biopsy to tumor board (T0: 1.3 months vs. T1: 0.9 months, p=0.001), to staging (T0: 1,1 months vs. T1: 0.75 months, p=0.707) and to therapy (T0: 3.0 months vs. T1: 2.0 months, p&lt;0.001) were shortened during pandemic. Classified by d'Amico, a significant shift towards higher risk groups was seen (p=0.024). Local staging showed an insignificant increase in locally advanced PCs. Metastatic diseases decreased from 10.3 % to 8.9% (p=0.433). Pathological staging showed pT3+ in 44.4% vs. 44.7% (p=0.565) and pN+ in 9.9 % vs 9.6% (p=0.899). Conclusion Regarding the diagnosis and treatment of PC, we could not demonstrate any delays due to the SARS-CoV-2-pandemic.</p>","PeriodicalId":23414,"journal":{"name":"Urologia Internationalis","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142372984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antibiotic prophylaxis of transrectal biopsy of the prostate - a plea for fosfomycin. 经直肠前列腺活检的抗生素预防措施--请求使用磷霉素。
IF 1.5 4区 医学 Q3 UROLOGY & NEPHROLOGY Pub Date : 2024-10-03 DOI: 10.1159/000541798
Philipp Julian Spachmann, Daniel Witt, Johannes Breyer, Stefan Denzinger, Maximilian Burger, Daniel Claudius Vergho, Wolfgang Otto, Marco Julius Schnabel

Introduction According to guidelines, transrectal random biopsy of the prostate (TRBP) is performed under antibiotic prophylaxis (AP). Fosfomycin-trometamol (FOS) is not approved in Germany, but TRBP as indication was listed in the product information falsely. Aim was to investigate infectious complications of TRBP under FOS as a single dose. Methods All TRBPs under FOS 3000 mg as a single dose between 1st of July 2020 and 30th of June 2021 at a university institution were recorded. 357 patients (41-85 years old, median 66) were included. 243 received first TRBP, 321 TRBP were MRI-fusionated. 10 to 22 cores were taken (median 14). PSA was 0.1 to 1224ng/ml (median 7.7ng/ml), prostate volume 5 to 263ml (median 50ml). Analysis was performed using Chi square test or Fisher's exact test, Mann-Whitney-U test, and t-test. Results Four patients suffered an infection (1.1%), without significant difference according to age (p=0.849), PSA (p=0.957), number of cores (p=0.905) and increase in volume (p=0.456). Limiting is the retrospective character. Conclusion The complication rate was 1.1%, FOS single dose therefore represents sufficient antibiotic prophylaxis for TRBP in this collective. FOS as a single dose should be re-evaluated in a prospective study to obtain approval in Germany for this indication.

导言:根据指南,经直肠随机前列腺活检(TRBP)应在抗生素预防(AP)下进行。德国未批准使用磷霉素-曲美他莫(FOS),但在产品信息中却虚假地将 TRBP 列为适应症。目的是调查单剂量 FOS 下 TRBP 的感染并发症。方法 记录了一家大学机构在 2020 年 7 月 1 日至 2021 年 6 月 30 日期间使用 FOS 3000 毫克单剂量 TRBP 的所有情况。共纳入 357 名患者(41-85 岁,中位数 66 岁)。243人接受了首次TRBP治疗,321人接受了核磁共振融合治疗。共采集了10至22个核芯(中位数为14个)。前列腺特异性抗原(PSA)为0.1至1224ng/ml(中位数为7.7ng/ml),前列腺体积为5至263ml(中位数为50ml)。采用卡方检验或费雪精确检验、Mann-Whitney-U 检验和 t 检验进行分析。结果 四名患者发生感染(1.1%),与年龄(P=0.849)、PSA(P=0.957)、核数(P=0.905)和体积增加(P=0.456)无显著差异。局限性在于其回顾性。结论 并发症发生率为 1.1%,因此单剂量 FOS 足够作为 TRBP 的抗生素预防用药。应在前瞻性研究中对 FOS 单剂量进行重新评估,以获得德国对这一适应症的批准。
{"title":"Antibiotic prophylaxis of transrectal biopsy of the prostate - a plea for fosfomycin.","authors":"Philipp Julian Spachmann, Daniel Witt, Johannes Breyer, Stefan Denzinger, Maximilian Burger, Daniel Claudius Vergho, Wolfgang Otto, Marco Julius Schnabel","doi":"10.1159/000541798","DOIUrl":"https://doi.org/10.1159/000541798","url":null,"abstract":"<p><p>Introduction According to guidelines, transrectal random biopsy of the prostate (TRBP) is performed under antibiotic prophylaxis (AP). Fosfomycin-trometamol (FOS) is not approved in Germany, but TRBP as indication was listed in the product information falsely. Aim was to investigate infectious complications of TRBP under FOS as a single dose. Methods All TRBPs under FOS 3000 mg as a single dose between 1st of July 2020 and 30th of June 2021 at a university institution were recorded. 357 patients (41-85 years old, median 66) were included. 243 received first TRBP, 321 TRBP were MRI-fusionated. 10 to 22 cores were taken (median 14). PSA was 0.1 to 1224ng/ml (median 7.7ng/ml), prostate volume 5 to 263ml (median 50ml). Analysis was performed using Chi square test or Fisher's exact test, Mann-Whitney-U test, and t-test. Results Four patients suffered an infection (1.1%), without significant difference according to age (p=0.849), PSA (p=0.957), number of cores (p=0.905) and increase in volume (p=0.456). Limiting is the retrospective character. Conclusion The complication rate was 1.1%, FOS single dose therefore represents sufficient antibiotic prophylaxis for TRBP in this collective. FOS as a single dose should be re-evaluated in a prospective study to obtain approval in Germany for this indication.</p>","PeriodicalId":23414,"journal":{"name":"Urologia Internationalis","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142372982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prediction of lesion-based treatment response after two cycles of Lu-177 PSMA treatment in metastatic castration-resistant prostate cancer using machine learning. 利用机器学习预测转移性阉割耐药前列腺癌患者接受两个周期 Lu-177 PSMA 治疗后基于病灶的治疗反应。
IF 1.5 4区 医学 Q3 UROLOGY & NEPHROLOGY Pub Date : 2024-09-30 DOI: 10.1159/000541628
Ogün BülBül, Demet Nak, Sibel Göksel

Introduction Lutetium-177 (Lu-177) prostate specific membrane antigen (PSMA) therapy is a radionuclide treatment that prolongs overall survival in metastatic castration-resistant prostate cancer (MCRPC). We aimed to predict lesion-based treatment response after Lu-177 PSMA treatment using machine learning with texture analysis data obtained from pretreatment Gallium-68 (Ga-68) PSMA PET/CT. Methods Eighty-three progressed, and 91 nonprogressed malignant foci on pretreatment Ga-68 PSMA PET/CT of 9 patients were used for analysis. Malignant foci with at least a 30% increase in Ga-68 PSMA uptake after two cycles of treatment were considered progressed lesions. All other changes in Ga-68 PSMA uptake of the lesions were considered nonprogressed lesions. The classifiers tried to predict progressed lesions. Results Logistic regression, Naive Bayes, and k-nearest neighbors' AUC values in detecting progressed lesions in the training group were 0.956, 0.942, and 0.950, respectively, and their accuracy was 87%, 85%, and 89%, respectively. The AUC values of the classifiers in the testing group were 0.937, 0.954, and 0.867, respectively, and their accuracy was 85%, 88%, and 79%, respectively. Conclusion Using machine learning with texture analysis data obtained from pretreatment Ga-68 PSMA PET/CT in MCRPC predicted lesion-based treatment response after two cycles of Lu-177 PSMA treatment.

导言:镥-177(Lu-177)前列腺特异性膜抗原(PSMA)疗法是一种放射性核素疗法,可延长转移性去势抵抗性前列腺癌(MCRPC)的总生存期。我们的目的是利用从治疗前镓-68 (Ga-68) PSMA PET/CT 中获得的纹理分析数据,通过机器学习预测 Lu-177 PSMA 治疗后基于病变的治疗反应。方法 对9例患者治疗前Ga-68 PSMA PET/CT上的83个进展期和91个非进展期恶性病灶进行分析。经过两个周期治疗后,Ga-68 PSMA 摄取至少增加 30% 的恶性病灶被视为进展病灶。病灶的Ga-68 PSMA摄取量的所有其他变化均被视为非进展病灶。分类器试图预测进展病灶。结果 Logistic 回归、Naive Bayes 和 k-nearest neighbors 检测训练组进展病灶的 AUC 值分别为 0.956、0.942 和 0.950,准确率分别为 87%、85% 和 89%。测试组中分类器的 AUC 值分别为 0.937、0.954 和 0.867,准确率分别为 85%、88% 和 79%。结论 利用机器学习和纹理分析数据,从MCRPC治疗前Ga-68 PSMA PET/CT中获得的数据可以预测两个周期Lu-177 PSMA治疗后基于病灶的治疗反应。
{"title":"Prediction of lesion-based treatment response after two cycles of Lu-177 PSMA treatment in metastatic castration-resistant prostate cancer using machine learning.","authors":"Ogün BülBül, Demet Nak, Sibel Göksel","doi":"10.1159/000541628","DOIUrl":"https://doi.org/10.1159/000541628","url":null,"abstract":"<p><p>Introduction Lutetium-177 (Lu-177) prostate specific membrane antigen (PSMA) therapy is a radionuclide treatment that prolongs overall survival in metastatic castration-resistant prostate cancer (MCRPC). We aimed to predict lesion-based treatment response after Lu-177 PSMA treatment using machine learning with texture analysis data obtained from pretreatment Gallium-68 (Ga-68) PSMA PET/CT. Methods Eighty-three progressed, and 91 nonprogressed malignant foci on pretreatment Ga-68 PSMA PET/CT of 9 patients were used for analysis. Malignant foci with at least a 30% increase in Ga-68 PSMA uptake after two cycles of treatment were considered progressed lesions. All other changes in Ga-68 PSMA uptake of the lesions were considered nonprogressed lesions. The classifiers tried to predict progressed lesions. Results Logistic regression, Naive Bayes, and k-nearest neighbors' AUC values in detecting progressed lesions in the training group were 0.956, 0.942, and 0.950, respectively, and their accuracy was 87%, 85%, and 89%, respectively. The AUC values of the classifiers in the testing group were 0.937, 0.954, and 0.867, respectively, and their accuracy was 85%, 88%, and 79%, respectively. Conclusion Using machine learning with texture analysis data obtained from pretreatment Ga-68 PSMA PET/CT in MCRPC predicted lesion-based treatment response after two cycles of Lu-177 PSMA treatment.</p>","PeriodicalId":23414,"journal":{"name":"Urologia Internationalis","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142354722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic Significance of Albumin-Globulin Ratio in Urachal Carcinoma. 尿道癌中白蛋白-球蛋白比值的预后意义
IF 1.5 4区 医学 Q3 UROLOGY & NEPHROLOGY Pub Date : 2024-09-27 DOI: 10.1159/000540665
Hengxin Chen, Menghai Wu, Minfeng Chen

Introduction: Although albumin-globulin ratio (AGR) has been used in the prognostic assessment of multiple solid malignancies, so far no research has confirmed the prognostic significance of AGR as a biomarker for urachal carcinoma. We analyzed the relationship between AGR and prognosis in urachal carcinoma, aiming to identify a promising prognostic biomarker for urachal carcinoma.

Methods: We reviewed the clinical data of 25 patients diagnosed with urachal carcinoma in the Xiangya Hospital, Central South University, from January 2008 to October 2021. The best cut-off value of preoperative AGR was determined according to the receiver operator characteristic curve. The Kaplan-Meier curve was used to analyze the effect of preoperative AGR on the overall survival (OS) and relapse-free survival (RFS) of patients. Cox proportional hazards model was used to analyze prognostic factors including preoperative AGR.

Results: The best cut-off value of preoperative AGR in urachal carcinoma patients is 1.45. Low preoperative AGR is significantly associated with worse OS and RFS. Univariate analysis and multivariate analysis indicated that low preoperative AGR is an independent and reliable factor to predict poor prognosis, OS, and RFS in urachal carcinoma patients.

Conclusion: Urachal carcinoma patients with low preoperative AGR have worse prognosis, and preoperative AGR is a valuable prognostic indicator for urachal carcinoma research.

引言虽然白蛋白-球蛋白比值(AGR)已被用于多种实体恶性肿瘤的预后评估,但迄今为止,还没有研究证实AGR作为泌尿道癌生物标志物的预后意义。我们分析了AGR与尿道癌预后的关系,旨在为尿道癌找到一个有希望的预后生物标志物:我们回顾了 2008 年 1 月至 2021 年 10 月期间在中南大学湘雅医院确诊的 25 例尿道癌患者的临床资料。根据接收者操作特征曲线确定术前 AGR 的最佳临界值。采用Kaplan-Meier曲线分析术前AGR对患者总生存期(OS)和无复发生存期(RFS)的影响。Cox比例危险模型用于分析包括术前AGR在内的预后因素:结果:尿道癌患者术前 AGR 的最佳临界值为 1.45。低术前AGR与较差的OS和RFS明显相关。单变量分析和多变量分析表明,术前低AGR是预测尿道癌患者预后不良、OS和RFS的独立可靠因素:结论:术前AGR较低的膀胱癌患者预后较差,术前AGR是膀胱癌研究中一个有价值的预后指标。
{"title":"Prognostic Significance of Albumin-Globulin Ratio in Urachal Carcinoma.","authors":"Hengxin Chen, Menghai Wu, Minfeng Chen","doi":"10.1159/000540665","DOIUrl":"https://doi.org/10.1159/000540665","url":null,"abstract":"<p><strong>Introduction: </strong>Although albumin-globulin ratio (AGR) has been used in the prognostic assessment of multiple solid malignancies, so far no research has confirmed the prognostic significance of AGR as a biomarker for urachal carcinoma. We analyzed the relationship between AGR and prognosis in urachal carcinoma, aiming to identify a promising prognostic biomarker for urachal carcinoma.</p><p><strong>Methods: </strong>We reviewed the clinical data of 25 patients diagnosed with urachal carcinoma in the Xiangya Hospital, Central South University, from January 2008 to October 2021. The best cut-off value of preoperative AGR was determined according to the receiver operator characteristic curve. The Kaplan-Meier curve was used to analyze the effect of preoperative AGR on the overall survival (OS) and relapse-free survival (RFS) of patients. Cox proportional hazards model was used to analyze prognostic factors including preoperative AGR.</p><p><strong>Results: </strong>The best cut-off value of preoperative AGR in urachal carcinoma patients is 1.45. Low preoperative AGR is significantly associated with worse OS and RFS. Univariate analysis and multivariate analysis indicated that low preoperative AGR is an independent and reliable factor to predict poor prognosis, OS, and RFS in urachal carcinoma patients.</p><p><strong>Conclusion: </strong>Urachal carcinoma patients with low preoperative AGR have worse prognosis, and preoperative AGR is a valuable prognostic indicator for urachal carcinoma research.</p>","PeriodicalId":23414,"journal":{"name":"Urologia Internationalis","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142354723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of tissue and urine microbiota in male, intervention naive patients with and without non-invasive bladder cancer. 男性非侵袭性膀胱癌患者和未接受干预的患者组织和尿液微生物群的比较。
IF 1.5 4区 医学 Q3 UROLOGY & NEPHROLOGY Pub Date : 2024-09-21 DOI: 10.1159/000541296
Muhammed S Ozer, Canet Incir, Huseyin A Yildiz, Muslim D Deger, Alper E Sarikaya, Yesim Tuncok, Gul Ergor, Nuran Esen, Volkan Sen, Ozan Bozkurt, Adil Esen

BACKGROUNDː To investigate the presence of dysbiosis in patients with naive bladder cancer. METHODSː Twelve male patients with non-invasive bladder cancer and twelve age-matched healthy males had midstream urine and tissue samples taken. A history of endourological interventions was determined as an exclusion criterion, ensuring that the study was designed solely with naïve participants. The bacterial 16s ribosomal RNA V3-V4 regions were used to examine urine and tissue samples. We compared the microbiota composition of the bladder cancer and control groups. RESULTSː Escherichia Shigella (p<0.001), Staphylococcus (p<0.001), Delftia (p<0.001), Acinetobacter (p<0.001), Corynebacterium (p<0.001), and Enhydrobacter (p<0.001) were abundant in bladder cancer tissue samples. Escherichia Shigella (p<0.001), Ureaplasma (p<0.001), Lactobacillus (p=0.005), Stenotrophomonas (p<0.001), Streptococcus (p<0.001), Corynebacterium (p<0.001), and Prevotella (p=0.039) were abundant in bladder cancer urine samples. Midstream urine has a sensitivity of 83% for detecting dysbiotic bacteria in cancer tissue. CONCLUSIONSː Our research is the first microbiota study of bladder cancer done with naive patients who have never had an endourological intervention. Escherichia Shigella, Staphylococcus, Acinetobacter, Enhydrobacter, Delftia, Corynebacterium, and Pseudomonas were detected as dysbiotic bacteria in bladder cancer. The sensitivity of the midstream urine sample in detecting dysbiosis in tissue is %83.

背景ː 研究天真膀胱癌患者体内是否存在菌群失调。方法ː 12 名男性非侵袭性膀胱癌患者和 12 名年龄匹配的健康男性采集了中段尿液和组织样本。将有过内科治疗史的患者作为排除标准,以确保该研究只针对未接受治疗的患者。我们使用细菌 16s 核糖体 RNA V3-V4 区域来检测尿液和组织样本。我们比较了膀胱癌组和对照组的微生物群组成。结果ː 在膀胱癌组织样本中,志贺氏埃希氏菌(p<0.001)、葡萄球菌(p<0.001)、Delftia(p<0.001)、Acinetobacter(p<0.001)、Corynebacterium(p<0.001)和 Enhydrobacter(p<0.001)大量存在。在膀胱癌尿液样本中,志贺氏大肠杆菌(p<0.001)、尿解脲原体(p<0.001)、乳酸杆菌(p=0.005)、血单胞菌(p<0.001)、链球菌(p<0.001)、棒状杆菌(p<0.001)和普雷沃特氏菌(p=0.039)大量存在。中段尿液检测癌症组织中菌群失调细菌的灵敏度为 83%。结论ː 我们的研究是首次对膀胱癌微生物群进行研究,研究对象是从未接受过尿道内介入治疗的天真患者。在膀胱癌中检测到的菌群失调细菌包括志贺氏菌、葡萄球菌、醋酸杆菌、恩氢杆菌、Delftia、棒状杆菌和假单胞菌。中段尿液样本检测组织中菌群失调的灵敏度为 83%。
{"title":"Comparison of tissue and urine microbiota in male, intervention naive patients with and without non-invasive bladder cancer.","authors":"Muhammed S Ozer, Canet Incir, Huseyin A Yildiz, Muslim D Deger, Alper E Sarikaya, Yesim Tuncok, Gul Ergor, Nuran Esen, Volkan Sen, Ozan Bozkurt, Adil Esen","doi":"10.1159/000541296","DOIUrl":"https://doi.org/10.1159/000541296","url":null,"abstract":"<p><p>BACKGROUNDː To investigate the presence of dysbiosis in patients with naive bladder cancer. METHODSː Twelve male patients with non-invasive bladder cancer and twelve age-matched healthy males had midstream urine and tissue samples taken. A history of endourological interventions was determined as an exclusion criterion, ensuring that the study was designed solely with naïve participants. The bacterial 16s ribosomal RNA V3-V4 regions were used to examine urine and tissue samples. We compared the microbiota composition of the bladder cancer and control groups. RESULTSː Escherichia Shigella (p&lt;0.001), Staphylococcus (p&lt;0.001), Delftia (p&lt;0.001), Acinetobacter (p&lt;0.001), Corynebacterium (p&lt;0.001), and Enhydrobacter (p&lt;0.001) were abundant in bladder cancer tissue samples. Escherichia Shigella (p&lt;0.001), Ureaplasma (p&lt;0.001), Lactobacillus (p=0.005), Stenotrophomonas (p&lt;0.001), Streptococcus (p&lt;0.001), Corynebacterium (p&lt;0.001), and Prevotella (p=0.039) were abundant in bladder cancer urine samples. Midstream urine has a sensitivity of 83% for detecting dysbiotic bacteria in cancer tissue. CONCLUSIONSː Our research is the first microbiota study of bladder cancer done with naive patients who have never had an endourological intervention. Escherichia Shigella, Staphylococcus, Acinetobacter, Enhydrobacter, Delftia, Corynebacterium, and Pseudomonas were detected as dysbiotic bacteria in bladder cancer. The sensitivity of the midstream urine sample in detecting dysbiosis in tissue is %83.</p>","PeriodicalId":23414,"journal":{"name":"Urologia Internationalis","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimizing Antibiotic Treatment for Urinary Tract Infections secondary to E. coli in Elderly Diabetic Patients: Considering Age and Blood Glucose Control. 优化老年糖尿病患者继发大肠杆菌尿路感染的抗生素治疗:考虑年龄和血糖控制。
IF 1.5 4区 医学 Q3 UROLOGY & NEPHROLOGY Pub Date : 2024-09-16 DOI: 10.1159/000541435
Baozhu Yi, Xiaowei Xu, Zhendong Lin, Youhua He, Shuaibin Wang

Introduction: In order to examine the susceptibility profile of Escherichia coli in urinary tract infections among elderly diabetic patients to support judicious and evidence-based antibiotic use.

Methods: From January 2021 to December 2022, urine culture results were analyzed to determine the distribution of pathogens, especially Escherichia coli, and their drug susceptibility.

Results: Escherichia coli infection was the most prevalent infection in elderly diabetic patients with urinary tract infections, accounting for 32.6% of cases. Moreover, this bacterium's multiple resistance rate (38.3%) was significantly higher than other bacteria's multiple resistance rate (χ2=81.644, P<0.05). Compared to older diabetic patients with optimal glucose control (HbA1c≤7.0%), patients with poor glycemic control (HbA1c>7.0%) had lower resistance rates to lactams and urine pH values were higher (P <0.05).

Conclusion: The most common cause of urinary tract infections (UTIs) is Escherichia coli, with advanced age and diabetes being the main risk factors. To optimize UTI treatment safety and efficacy, antibiotics should be administered based on the patient's age and blood glucose control.

引言为了研究老年糖尿病患者尿路感染中大肠埃希菌的药敏谱,以支持明智、循证地使用抗生素:方法:对2021年1月至2022年12月的尿培养结果进行分析,以确定病原体(尤其是大肠埃希菌)的分布及其药物敏感性:结果:大肠埃希菌感染是老年糖尿病患者尿路感染中最常见的感染,占 32.6%。此外,该细菌的多重耐药率(38.3%)明显高于其他细菌的多重耐药率(χ2=81.644,P<0.05)。与血糖控制较好(HbA1c≤7.0%)的老年糖尿病患者相比,血糖控制较差(HbA1c>7.0%)的患者对内酰胺类药物的耐药率较低,尿液 pH 值较高(P<0.05):尿路感染(UTI)最常见的病因是大肠埃希菌,高龄和糖尿病是主要的风险因素。为优化 UTI 治疗的安全性和有效性,应根据患者的年龄和血糖控制情况使用抗生素。
{"title":"Optimizing Antibiotic Treatment for Urinary Tract Infections secondary to E. coli in Elderly Diabetic Patients: Considering Age and Blood Glucose Control.","authors":"Baozhu Yi, Xiaowei Xu, Zhendong Lin, Youhua He, Shuaibin Wang","doi":"10.1159/000541435","DOIUrl":"https://doi.org/10.1159/000541435","url":null,"abstract":"<p><strong>Introduction: </strong>In order to examine the susceptibility profile of Escherichia coli in urinary tract infections among elderly diabetic patients to support judicious and evidence-based antibiotic use.</p><p><strong>Methods: </strong>From January 2021 to December 2022, urine culture results were analyzed to determine the distribution of pathogens, especially Escherichia coli, and their drug susceptibility.</p><p><strong>Results: </strong>Escherichia coli infection was the most prevalent infection in elderly diabetic patients with urinary tract infections, accounting for 32.6% of cases. Moreover, this bacterium's multiple resistance rate (38.3%) was significantly higher than other bacteria's multiple resistance rate (χ2=81.644, P&lt;0.05). Compared to older diabetic patients with optimal glucose control (HbA1c≤7.0%), patients with poor glycemic control (HbA1c&gt;7.0%) had lower resistance rates to lactams and urine pH values were higher (P &lt;0.05).</p><p><strong>Conclusion: </strong>The most common cause of urinary tract infections (UTIs) is Escherichia coli, with advanced age and diabetes being the main risk factors. To optimize UTI treatment safety and efficacy, antibiotics should be administered based on the patient's age and blood glucose control.</p>","PeriodicalId":23414,"journal":{"name":"Urologia Internationalis","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of eliminating artificial hydronephrosis and creating artificial hydronephrosis in percutaneous nephrolithotomy in oblique supine position. 在斜仰卧位经皮肾镜碎石术中消除人工肾积水和建立人工肾积水的比较。
IF 1.5 4区 医学 Q3 UROLOGY & NEPHROLOGY Pub Date : 2024-09-14 DOI: 10.1159/000541407
Yuanshan Guo, Caipeng Qin, Chao Li, Xin Xu, Heran Cao, Lei Guo, Jin Zhang, Shen Li, Tao Xu

Introduction: The safety and effectiveness of percutaneous nephroscopic surgery without artificial hydronephrosis remain controversial, and there are few relevant studies. This retrospective study aimed to compare the efficacy of two different methods of eliminating and creating artificial hydronephrosis in percutaneous nephrolithotomy(PCNL) in the oblique supine position.

Methods: This is a retrospective study. A total of 162 patients who underwent PCNL in an oblique supine position at our hospital were divided into two groups according to the surgical method: the free artificial hydronephrosis group (Group A) and the artificial hydronephrosis group (Group B). Group A was directly treated with PCNL under ultrasound guidance and group B was treated with artificial hydronephrosis before PCNL. Several outcomes were measured, including operation time, stone clearance rate, and incidence of complications.

Results: The operation time in Group A lower than that in Group B, and the incidence of sepsis was significantly lower in group A than in Group B (P<0.05). There was no statistical difference in stone clearance rate, success rate of primary establishment of puncture channel, unilateral change in perioperative red blood cell count, change in perioperative renal function, and perioperative complications (except sepsis) between the two groups (P>0.05).

Conclusion: For experienced physicians, percutaneous nephrolithotomy without artificial hydronephrosis in an oblique supine position can be attempted to reduce the number of surgical steps without affecting the stone clearance rate and increasing the occurrence of complications.

导言:无人工肾积水的经皮肾镜手术的安全性和有效性仍存在争议,相关研究也很少。这项回顾性研究旨在比较斜仰卧位经皮肾镜取石术(PCNL)中消除和建立人工肾积水的两种不同方法的疗效:这是一项回顾性研究。方法:这是一项回顾性研究,共选取了 162 例在我院接受斜仰卧位经皮肾镜取石术的患者,根据手术方法分为两组:游离人工肾积水组(A 组)和人工肾积水组(B 组)。A 组在超声引导下直接进行 PCNL 治疗,B 组在 PCNL 之前进行人工肾积水治疗。对手术时间、结石清除率和并发症发生率等几项结果进行了测量:结果:A 组的手术时间低于 B 组,脓毒症的发生率也明显低于 B 组(P<0.05)。两组在结石清除率、穿刺通道初建成功率、围术期单侧红细胞计数变化、围术期肾功能变化、围术期并发症(脓毒症除外)等方面无统计学差异(P>0.05):对于有经验的医生来说,可以尝试在斜仰卧位下进行经皮肾镜取石术而不进行人工肾积水,以减少手术步骤,同时不影响结石清除率和增加并发症的发生率。
{"title":"Comparison of eliminating artificial hydronephrosis and creating artificial hydronephrosis in percutaneous nephrolithotomy in oblique supine position.","authors":"Yuanshan Guo, Caipeng Qin, Chao Li, Xin Xu, Heran Cao, Lei Guo, Jin Zhang, Shen Li, Tao Xu","doi":"10.1159/000541407","DOIUrl":"https://doi.org/10.1159/000541407","url":null,"abstract":"<p><strong>Introduction: </strong>The safety and effectiveness of percutaneous nephroscopic surgery without artificial hydronephrosis remain controversial, and there are few relevant studies. This retrospective study aimed to compare the efficacy of two different methods of eliminating and creating artificial hydronephrosis in percutaneous nephrolithotomy(PCNL) in the oblique supine position.</p><p><strong>Methods: </strong>This is a retrospective study. A total of 162 patients who underwent PCNL in an oblique supine position at our hospital were divided into two groups according to the surgical method: the free artificial hydronephrosis group (Group A) and the artificial hydronephrosis group (Group B). Group A was directly treated with PCNL under ultrasound guidance and group B was treated with artificial hydronephrosis before PCNL. Several outcomes were measured, including operation time, stone clearance rate, and incidence of complications.</p><p><strong>Results: </strong>The operation time in Group A lower than that in Group B, and the incidence of sepsis was significantly lower in group A than in Group B (P&lt;0.05). There was no statistical difference in stone clearance rate, success rate of primary establishment of puncture channel, unilateral change in perioperative red blood cell count, change in perioperative renal function, and perioperative complications (except sepsis) between the two groups (P&gt;0.05).</p><p><strong>Conclusion: </strong>For experienced physicians, percutaneous nephrolithotomy without artificial hydronephrosis in an oblique supine position can be attempted to reduce the number of surgical steps without affecting the stone clearance rate and increasing the occurrence of complications.</p>","PeriodicalId":23414,"journal":{"name":"Urologia Internationalis","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Urologia Internationalis
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1